European Commission approves nasal spray vaccine FLUENZ for children

AstraZeneca announced today that the European Commission has granted marketing authorisation to FLUENZ Influenza Vaccine, a nasally administered live attenuated influenza vaccine, for prevention of seasonal influenza for children 24 months to less than 18 years of age...

Read the full story >>

More pharmaceutical & life science news:

FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo®

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

Bayer and Zydus Cadila sign joint venture agreement to strengthen pharmaceutical business in India

Owen Mumford Limited appoints new General Manager

Lundbeck Research USA, Inc. & BioFocus sign compound management agreement

EMD Millipore announces change in supply chain of insulin for cell culture media

Upcoming conferences, events & exhibitions:

The Drug Development Process – From Discovery to Commercialization
2 - 4 March 2011, Berlin, Germany

Validation of Computer Systems
14 - 15 March 2011, Berlin, Germany

SBS 17th Annual Conference & Exhibition Advancing the Science of Drug Discovery
27 - 31 March 2011, Gaylord Palms Resort & Convention Center Orlando, Florida, USA

LogiPharma Europe 2011
29 - 31 March 2011, Geneva, Switzerland

CMC Regulatory Compliance for Biopharmaceuticals and Biologics
30 March - 1 April 2011, Berlin, Germany

BioCapital Europe 2011
31 March 2011, Amsterdam, Netherlands